Physiomics Share Discussion Threads

[the stigologist] 09/5/2020 22:01

The UK Government has been a Company-maker during this crisis. Otherwise small unloved underowned under-researched undervalued companies gained huge prominence because a desperate Government needed to expand and 'ramp up' UK diagnostics sector capacity urgently.

GDR Genedrive and ODX Omega Diagnostics were two major beneficiaries. Away from Covid emergency the Government have also been funding and supporting PYC Physiomics to develop what could become nothing less than a universal cancer decision support system

In the middle of recent market crash (March 10th) PYC announced a further funding award from UK Government's NIHR of c£150k to add to previous awards they'd received of £199k to date

Interestingly in the smaller print towards end of statement they talked about three items which should see this Company develop significantly and earn much greater prominence



1. how this funding round was generally seen as accelerating companies towards another later stage funding rounds which tend to be in the range of c.£1m (a current £3m Company gaining access to c.£1m of Govt funding to accelerate a product development would be pretty huge and transformational news)

2. that they remained in discussions with 'established players' in the Personalised Medicine space. Most of the 'established players' in this space who've identified the opportunity are Billion+ unicorns (in the UK likes of BenevolentAI, Exscientia, maybe even PYC's Oxford Science Park neighbour Sensyne Health)

3. they talked about gaining regulatory approval for their tool "in Europe and beyond" and alluded to making their existing 'prostate cancer dosing app' more 'universal' by applying it to other cancer types and cancer drugs.

In essence what they are working towards but maybe hiding their light under a bushel about at present is a universal AI/ML driven Personalised Medicine 'Cancer Decision Support System'. If they pulled that off you're talking a Company potentially worth hundreds of millions. They have the impressive backing of numerous well respected Institutions in the cancer oncology space as their projects/partnerships to date demonstrate but they look set to go to a whole new level soon.

All of these 3 items if they eventuate could be game changing for a Company presently valued at only c.£3m

This project has so far been a sideshow project for PYC from their 'bread and butter' business which is providing Modelling and Simulation software and consulting expertise (embodied in their Virtual Tumour model of cancer) to bios/pharmas like Bicycle Therapeutics and Merck in their cancer drug development programmes

[the stigologist] 08/5/2020 23:25

PYC Telegram group

[myamay16] 08/5/2020 20:49

Apologies,
On advfn 650k shown on 7th at 08:58, which would have been a buy.
On Lse 650k shown on 6th at 08:58, which would have been a sell.

[phil mcavity] 08/5/2020 18:33

"Do you think Rabia would fancy me? I am 58"

Eejit.
Is the Pope Catholic?

[myamay16] 08/5/2020 13:34

650k was at 08:58 on the 6th, comparing the bid and offer value at that time it looks like a buy.

[herb clark] 08/5/2020 13:18

Was that a 650 k buy?

[the stigologist] 08/5/2020 03:17

2 weekly candle closes above the last one years heavy constricted 'congestion' period

Golden Cross incoming also

Very strong technical signals

Volume precedes Price

[spacedust] 07/5/2020 14:50

Volsung she is young enough to be your.......

[spacedust] 07/5/2020 14:19

She looks like a uni student

[chrismick] 07/5/2020 12:32

When we get to a quid you never know lol

[volsung] 07/5/2020 11:42

Do you think Rabia would fancy me? I am 58

[the stigologist] 07/5/2020 11:38

Rabia Khan has been identified as an 'Industry star' and up and coming person

She speaks for SENS at lots of Industry conferences on the general subject of AI

She recently spoke at a Conference about 'in-silico clinical trials'. SENS don't have any involvement with Bios/Pharmas doing 'in silico clinical trials' that is an area Physiomics operate in and have a long history, great clients, repeat business, publised academic papers on etc

Given that SENS are neighbours of PYC and their employees do know each other/communicate I think it's interesting to show that we/they are plugged in and highly regarded in their industry.

[spacedust] 07/5/2020 10:20

Davis moyez works for West ham utd

[herb clark] 07/5/2020 08:38

Stig. What is the significance for PYC?

[davevt] 07/5/2020 08:29

who cares what a woman who works at a completely different company does 😂

[the stigologist] 07/5/2020 02:59

Rabia Khan of our Oxford Science Park neighbours SENS (and also formerly BenevolentAI)



Rabia Khan

Sensyne Health PLC

Chief of Translational Medicine

Rabia Khan is chief of translational medicine at Sensyne Health, a health care technology company focused on accelerating the discovery and development of new medicines and improving patient care. This is achieved through the analysis of real-world evidence from large databases of anonymized patient data in collaboration with Nationa Health Service Trusts in the UK.

Sensyne Health is listed on the London Stock Exchange's AIM and is based in the Schrödinger Building in Oxford Science Park.

Before her current role, Khan was vice president of systems medicine at Sensyne Health. She also previously worked for BenevolantAI as an associate director of strategy and planning.

Khan has a PhD in human/medical genetics from McGill University and a master’s degree in business administration from Concordia University.

[spacedust] 06/5/2020 10:46

Jim the cunning forgot to mention that he sold his shares at 8p

[the stigologist] 05/5/2020 20:44

Dr Jim Millen the CEO in his blog this week said the following :-

" Personalised medicine is a move away from a one-size-fits-all approach to cancer treatment, where targeted therapies are used to achieve the best outcomes in the management of individual patients based on their genetic makeup and/or their metabolic response. At present we are developing our first personalised oncology tool, intended for use in personalising the dose of docetaxel in late-stage prostate cancer patients. The tool harnesses AI learning and big data to identify key factors linking dose, toxicity and efficacy and is the subject of a recent National Institute of Health Research (NIHR) award"

and promised :-

"Over the coming months we will look at each of these topics individually and explain in greater detail how we are involved, and the opportunities and challenges they present to us and the sector as a whole."

[johntopdog] 05/5/2020 19:17

Davevt...is this another scam share going nowhere..looks that way

[the stigologist] 05/5/2020 18:22

The UK Government has been a Company maker during this crisis. Otherwise small unloved underowned underresearched undervalued companies gained huge prominence because a desperate Government needed to expand and 'ramp up' UK diagnostics sector capacity urgently.

GDR Genedrive and ODX Omega Diagnostics were two major beneficiaries. Away from Covid emergency the Government have also been funding and supporting PYC Physiomics to develop what could become nothing less than a universal cancer decision support system

In the middle of recent market crash (March 10th) PYC announced a further funding award from UK Government's NIHR of c£150k to add to previous awards they'd received of £199k to date

Interestingly in the smaller print towards end of statement they talked about three items which should see this Company develop significantly and earn much greater prominence



1. how this funding round was generally seen as accelerating companies towards another later stage funding rounds which tend to be in the range of c.£1m (a current £3m Company gaining access to c.£1m of Govt funding to accelerate a product development would be pretty huge and transformational news)

2. that they remained in discussions with 'established players' in the Personalised Medicine space. Most of the 'established players' in this space who've identified the opportunity are Billion+ unicorns (in the UK likes of BenevolentAI, Exscientia, maybe even PYC's Oxford Science Park neighbour Sensyne Health)

3. they talked about gaining regualtory approval for their tool "in Europe and beyond" and alluded to making their existing 'prostate cancer dosing app' more 'universal' by applying it to other cancer types and cancer drugs.

In essence what they are working towards but maybe hiding their light under a bushel about at present is a universal AI/ML driven Personalised Medicine 'Cancer Decision Support System'. If they pulled that off you're talking a Company potentially worth hundreds of millions. They have the impressive backing of numerous well respected Institutions in cancer space as their projects/partnerships to date demonstrate but they look set to go to a whole new level soon.

All of these 3 items if they eventuate could be game changing for a Company presently valued at only £3m

This project has so far been a sideshow project for PYC from their 'bread and butter' business which is providing Modelling and Simulation software and consulting expertise (embodied in their Virtual Tumour model of cancer) to bios/pharmas like Bicycle Therapeutucs and Merck in their cancer drug development programmes

[volsung] 05/5/2020 14:19

Last tranche bought for 5.28p

[datait] 05/5/2020 10:26

bobby baw bit hahaha